0
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Constitutive Growth Hormone Secretion in Sheep after Hypothalamopituitary Disconnection and the Direct in vivo Pituitary Effect of Growth Hormone Releasing Peptide 6

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The effect of hypothalamopituitary disconnection (HPD) on growth hormone (GH) secretion was studied in sheep. Plasma GH levels were measured in serial blood samples (10 min × 6-8 h) taken from 12 Romney wethers and 5 ewes which had undergone HPD 40-506 days earlier and from 4 wethers (10 min × 7 h) to serve as controls. Five wethers and 5 ewes were taken ∼300 days after HPD and injected with vehicle or 10 µg/kg of the synthetic hexapeptide growth hormone-releasing peptide 6 (GHRP-6); GH responses were monitored. In a second series of sheep, 4 wethers and 6 HPD wethers were given saline, 0.5 µg/kg of synthetic growth hormone-releasing factor (GRF) or 5 µg/kg GHRP-6 and were blood-sampled to measure the plasma GH response. A further group of 4 HPD wethers and 3 control wethers were killed and the anterior pituitary glands collected for the quantification of GH and LHβ mRNA by Northern analysis. Three HPD wethers and 1 HPD ewe and 1 control ewe were killed and their brains were perfused; the hypothalami were sectioned and immunostained for the presence of GRF-containing fibres in the median eminence. Normal episodic GH secretion was abolished by HPD in both wethers and ewes but plasma values did not fall below the assay detection limit, indicating constitutive secretion. Northern blot analyses showed that the GH mRNA was detectable in HPD wethers at a lower (p < 0.05) level than in control animals but mRNA for LHβ was undetectable in the HPD wethers. Immunohistochemistry revealed GRF-positive staining in the median eminence of the controls but GRF-positive staining was not seen below the operation site in the median eminence of the HPD animals. In the first series, 3/5 wethers and 3/5 of the ewes responded to GHRP-6 challenge; the magnitude of the response was similar in both sexes. In the second series, responses to GRF were lower (48%) (p < 0.03) in HPD wethers than in control wethers, and responses to GHRP-6 were much lower (p < 0.01) than those to GRF in both controls and HPD wethers. These studies show that HPD removes GRF inputs to the pituitary gland and abolishes pulsatile GH secretion in most cases but constitutive non-pulsatile secretion continues. The HPD wether pituitary glands had lower GH mRNA levels than controls. Accordingly, HPD sheep were able to respond to a single injection of GRF although the response was half that seen in control animals. We conclude that constitutive synthesis and secretion of GH continues in the isolated pituitary gland but hypothalamic input is required for pulsatile secretion. A response to GHRP-6 in HPD sheep indicates a pituitary site of action for this peptide. GHRP-6 is less potent than GRF in vivo.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1994
          1994
          09 April 2008
          : 60
          : 1
          : 76-86
          Affiliations
          aPrince Henry’s Institute of Medical Research, Clayton, Vic., and bDepartment of Medicine, Flinders University, Bedford Park, S.A., Australia
          Article
          126722 Neuroendocrinology 1994;60:76–86
          10.1159/000126722
          8090285
          © 1994 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          Page count
          Pages: 11
          Categories
          Growth Hormone Regulation

          Comments

          Comment on this article